O-063 First U.S. multicenter experience using the pipeline flex embolization device with shield technology for treatment of intracranial aneurysms

ConclusionOur study is the first to report the early experience with the newly FDA-approved PED Flex with Shield technology amongst US centers. Our results are comparable with non-US, international studies showing a high technical success rate and safe peri-procedural angiographic and patient outcome. Longer follow-up will be needed to provide more robust data on angiographic and patient outcomes.Disclosures A. Kuhn: None. J. Singh: None. A. Abdelsalam: None. V. Saini: None. J. Burks: None. G. Cortez: None. R. Abbas: None. M. Pervez: None. H. Saei: None. S. Burke: None. M. Salem: None. J. Vivanco-Suarez: None. R. Kutcher-Diaz: None. M. Bounajem: None. V. Naragum: None. F. Massari: None. S. Marwah: None. M. Gounis: None. A. Hassan: 1; C; GE Healthcare and Valley Baptist. 2; C; Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care a. A. Malek: 2; C; CereVasc Inc.. 4; C; CereVasc Inc. G. Dabus: 2; C; Medtronic, Microvention, Cerenovus, Penumbra, Stryker, InNeuroCo, Route 92. I. Linfante: 2; C; Medtronic, Cerenovus. 4; C; InNeuroCo, Deinde, Prometeous, Three Rivers, Prolong Pharmaceuticals. S. Tjoumakaris: 2; C; Medtronic and Microvention (funds paid to institution, not personally). P. Jabbour: 2; C; Medtronic, Microvention and Cerus. J. Burkhardt: None. B. Jankowitz: None. F. Mudassir: None. S. Ortega Gutierrez: None. R. Grandhi: None. ...
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: SNIS 20th annual meeting oral abstracts Source Type: research